These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 3121395)
21. Use of purified gonadotrophins for ovarian stimulation in IVF. Jones GS Clin Obstet Gynaecol; 1985 Dec; 12(4):775-84. PubMed ID: 3938687 [No Abstract] [Full Text] [Related]
22. Ovarian hyperstimulation for in-vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotrophins. Wildt L; Diedrich K; van der Ven H; al Hasani S; Hübner H; Klasen R Hum Reprod; 1986 Jan; 1(1):15-9. PubMed ID: 2971082 [TBL] [Abstract][Full Text] [Related]
23. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer]. Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462 [TBL] [Abstract][Full Text] [Related]
24. Selection of agents for enhanced follicular recruitment in an in vitro fertilization and embryo replacement treatment program. Quigley MM Ann N Y Acad Sci; 1985; 442():96-111. PubMed ID: 3925848 [TBL] [Abstract][Full Text] [Related]
26. [A study of the controlled ovarian hyperstimulation using GnRH agonist and pure FSH in in vitro fertilization-embryo transfer and gamete intrafallopian transfer program]. Usui A Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1431-8. PubMed ID: 2511261 [TBL] [Abstract][Full Text] [Related]
27. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis. Dahan MH; Agdi M; Shehata F; Son W; Tan SL Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801 [TBL] [Abstract][Full Text] [Related]
28. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme. Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103 [TBL] [Abstract][Full Text] [Related]
29. Delaying human chorionic gonadotropin administration in human menopausal gonadotropin-induced cycles decreases successful in vitro fertilization of human oocytes. Laufer N; DeCherney AH; Tarlatzis BC; Zuckerman AL; Polan ML; Dlugi AM; Graebe R; Barnea ER; Naftolin F Fertil Steril; 1984 Aug; 42(2):198-203. PubMed ID: 6430722 [TBL] [Abstract][Full Text] [Related]
30. Ovarian superstimulation in the treatment of infertility due to peritubal and periovarian adhesions. Aboulghar MA; Mansour RT; Serour GI Fertil Steril; 1989 May; 51(5):834-7. PubMed ID: 2707459 [TBL] [Abstract][Full Text] [Related]
31. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study. Tan SL; Balen A; el Hussein E; Campbell S; Jacobs HS Fertil Steril; 1992 Aug; 58(2):378-83. PubMed ID: 1633906 [TBL] [Abstract][Full Text] [Related]
32. Combined diagnostic laparoscopy and follicular aspiration for human in vitro fertilization. Shoham Z; Barash A; Yemini M; Borenstein R Acta Obstet Gynecol Scand; 1990; 69(1):23-6. PubMed ID: 2140662 [TBL] [Abstract][Full Text] [Related]
33. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849 [TBL] [Abstract][Full Text] [Related]
34. Determination of the efficiency of controlled ovarian hyperstimulation in the gonadotropin-releasing hormone agonist-suppression cycle using the initial follicle count during gonadotropin stimulation. Huang FJ; Chang SY; Tsai MY; Kung FT; Wu JF; Chang HW J Assist Reprod Genet; 2001 Feb; 18(2):91-6. PubMed ID: 11285987 [TBL] [Abstract][Full Text] [Related]
35. Timing of oocyte retrieval in cycles with a spontaneous luteinizing hormone surge in a large in vitro fertilization program. Droesch K; Muasher SJ; Kreiner D; Jones GS; Acosta AA; Rosenwaks Z Fertil Steril; 1988 Sep; 50(3):451-6. PubMed ID: 3137100 [TBL] [Abstract][Full Text] [Related]
36. Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin-releasing hormone analog and menotropins. Herman A; Ron-El R; Golan A; Raziel A; Soffer Y; Caspi E Fertil Steril; 1990 Jan; 53(1):92-6. PubMed ID: 2104811 [TBL] [Abstract][Full Text] [Related]
37. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles. Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360 [TBL] [Abstract][Full Text] [Related]
38. Luteinizing hormone increases estradiol secretion but has no effect on progesterone concentrations in the late follicular phase of in vitro fertilization cycles in women treated with gonadotropin-releasing hormone agonist and follicle-stimulating hormone. Adonakis G; Deshpande N; Yates RW; Fleming R Fertil Steril; 1998 Mar; 69(3):450-3. PubMed ID: 9531875 [TBL] [Abstract][Full Text] [Related]
39. [Smoothing Gan Reinforcing Shen Method Adjuvantly Treated Poor Response of Diminished Ovari- an Reserve Patients in in vitro Fertilization and Embryo Transfer: a Clinical Study]. Zhang Z; Zhang XH; He TY Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Oct; 35(10):1170-4. PubMed ID: 26677665 [TBL] [Abstract][Full Text] [Related]
40. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer. Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]